NCT06125717View on ClinicalTrials.gov

Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 2, 2022

Primary Completion Date

March 13, 2023

Study Completion Date

March 13, 2023

Conditions
Influenza
Interventions
BIOLOGICAL

H1 influenza antigen

Either 7.5 μg or 15 μg of the H1 influenza antigen

Trial Locations (3)

M9W 4L6

Centricity Research Toronto, Toronto

J7J 2K8

Centricity Research Mirabel, Mirabel

H9R 4S3

Centricity Research Pointe-Claire, Pointe-Claire

Sponsors
All Listed Sponsors
collaborator

ICON plc

INDUSTRY

collaborator

Q2 Solutions

INDUSTRY

collaborator

Centricity Research

UNKNOWN

lead

Vaxess Technologies

INDUSTRY